www.curasight.com Open in urlscan Pro
52.174.176.76  Public Scan

Form analysis
3 forms found in the DOM

/search/

<form action="/search/">
  <input aria-label="Search" class="_searchbox" placeholder="Search" name="q" value="" autocomplete="off"><button aria-label="Submit search"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792">
      <use xlink:href="#svg-Search"></use>
    </svg></button>
  <div class="_instantsearch" data-nohits="No results found"></div>
</form>

/search/

<form action="/search/">
  <input aria-label="Search" class="_searchbox" placeholder="Search" name="q" value="" autocomplete="off"><button aria-label="Submit search"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792">
      <use xlink:href="#svg-Search"></use>
    </svg></button>
  <div class="_instantsearch" data-nohits="No results found"></div>
</form>

POST //publish.ne.cision.com/Subscription/Subscribe

<form action="//publish.ne.cision.com/Subscription/Subscribe" method="post" class="_subscribe">
  <input type="hidden" name="subscriptionUniqueIdentifier" value="3094420cd5">
  <input type="hidden" name="Replylanguage" value="en">
  <div class="_fields">
    <div id="5088283820538051"></div>
    <input style="display: none;" name="Language" type="checkbox" checked="" value="en">
    <h3>Choose type</h3>
    <div class="types">
      <label><input name="informationtype" type="checkbox" value="kmk,rpt,rdv"><span>Financial reports</span></label>
      <label><input name="informationtype" type="checkbox" value="prm"><span>Press releases</span></label>
    </div>
    <label>
      <span>E-mail</span>
      <input required="" type="email" name="Email" placeholder="E-mail">
      <div class="_result _fail">Something went wrong - please make sure you entered the correct email.</div>
    </label>
    <button><span>Subscribe</span></button>
  </div>
  <div class="_result _success">Thank you. You will get an e-mail message to activate your subscription.</div>
</form>

Text Content

Skip to main contentSkip to navigationSkip to search
Menu Close
11.44 DKK +6.92% | 27 Oct, 2022


 * About Us
   * Management Team
   * Board of Directors
   * History
 * Technology
   * uTRACE®
   * uTREAT®
   * uPAR Theranostics
   * Publications
 * Pipeline
 * News and media
   * Press releases
   * News
   * Curasight in the Media
   * Conferences
   * Subscribe
 * Investor
   * Curasight as an investment
   * Financial reports
   * The Share
   * General meetings
   * Calendar & Events
   * Corporate Governance
   * Analyst coverage
   * IPO 2020
   * Warrants 2021
 * Contact





CURASIGHT - PROVIDING ANSWERS FOR CANCER PATIENTS


CURASIGHT IS ON A MISSION TO IMPROVE THE LIVES OF MILLIONS OF PEOPLE WITH CANCER


CURASIGHT – A DANISH BIOTECH COMPANY THAT DEVELOPS A MORE GENTLE AND EFFICIENT
DETECTION AND TREATMENT OF CANCER

Curasight’s team are the pioneers behind the novel uPAR Theranostics technology.
The technology minimizes irradiation of healthy tissue by combining the targeted
uTREAT® radiation therapy, with the precise uTRACE® diagnostics. Several
investigator-initiated phase II clinical trials have been completed or are
currently undertaken.






CURASIGHT WAS LISTED ON SPOTLIGHT STOCK MARKET IN OCTOBER 2020. SEE THE
INFORMATION VIDEO FROM THE INITIAL PUBLIC OFFERING EXPLAINING HOW THE TECHNOLOGY
WORKS.


CLINICAL PROJECT LEAD

Exciting opportunity to lead the clinical program
for the groundbreaking Theranostics technology for several indications in
preparation for a global commercial launch.

Read more and apply


LATEST PRESS RELEASES


CURASIGHT INITIATES PRE-CLINICAL STUDIES WITH UTREAT[®] THERAPY IN HEAD AND NECK
CANCER (HNSCC) AND NEUROENDOCRINE TUMORS (NET)

October 13, 2022
 | Regulatory
Read more


TRANSACTION WITH SHARES IN CURASIGHT A/S MADE BY MANAGERIAL EMPLOYEE

September 4, 2022
 | Regulatory
Read more


CURASIGHT TO PRESENT AT HC ANDERSEN CAPITAL

August 25, 2022
 | Regulatory
Read more


COMPANY

Curasight is a pioneer in the field of exploiting a novel Positron Emissions
Tomography (PET) imaging platform targeting the urokinase-type plasminogen
activator receptor (“uPAR”). The technology provides improved diagnosis and
treatment in multiple cancer types, most notably for brain and prostate cancer.

Curasight – the company


TECHNOLOGY

Curasight builds its novel uPAR-PET imaging approach on a deep understanding of
the uPAR system and it’s role in cancer, together with extensive experience with
translational molecular imaging, which has been obtained through more than a
decade of research at Rigshospitalet and University of Copenhagen.

Curasight’s technology


PIPELINE

Curasight is focused on addressing the need for improved diagnosis and treatment
of brain and prostate cancer. Curasight build on its foundation of pioneering
research and development within uPAR-PET Imaging. Our clinical development
efforts include a program to develop a first-in-class uPAR-PET imaging ligand
which is currently in phase II clinical testing.

Curasight’s pipeline


BE PART OF FUNDING THE JOURNEY TO THE CANCER TREATMENT OF TOMORROW

With aging populations, increased number of cancers, wider use of nuclear
medicine and introductions of new radiopharmaceuticals around the world as
growth factors, the market is expected to grow rapidly. Based on promising
results, Curasight’s Board and management projects that their technology could
become game-changing in the management of cancer patients.

Invest in Curasight


SUBSCRIBE

Subscribe to get the latest news first.


CHOOSE TYPE

Financial reports Press releases
E-mail
Something went wrong - please make sure you entered the correct email.
Subscribe
Thank you. You will get an e-mail message to activate your subscription.

Curasight – a Danish biotech company that develops a more gentle and efficient
detection and treatment of cancer.

Curasight's team are the pioneers behind the novel uPAR Theranostics technology.
The technology minimizes irradiation of healthy tissue by combining the targeted
uTREAT® radiation therapy with the precise uTRACE® diagnostics. Several
investigator-initiated phase II clinical trials have been completed or are
currently undertaken.

 * News and media
 * Contact
 * Terms of use

Copyright 2022 © Curasight

This website uses cookies to provide the best possible user experience. If you
continue without making any changes you allow this. Read more about cookies here

Accept

Close